These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24049176)

  • 21. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus.
    Zhao H; Lin W; Kumthip K; Cheng D; Fusco DN; Hofmann O; Jilg N; Tai AW; Goto K; Zhang L; Hide W; Jang JY; Peng LF; Chung RT
    J Hepatol; 2012 Feb; 56(2):326-33. PubMed ID: 21888876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
    Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
    PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.
    Gottwein JM; Scheel TK; Jensen TB; Lademann JB; Prentoe JC; Knudsen ML; Hoegh AM; Bukh J
    Hepatology; 2009 Feb; 49(2):364-77. PubMed ID: 19148942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.
    Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M
    Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of hepatitis B and C virus envelope glycoproteins.
    Jeulin H; Velay A; Murray J; Schvoerer E
    World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antimalarial ferroquine is an inhibitor of hepatitis C virus.
    Vausselin T; Calland N; Belouzard S; Descamps V; Douam F; Helle F; François C; Lavillette D; Duverlie G; Wahid A; Fénéant L; Cocquerel L; Guérardel Y; Wychowski C; Biot C; Dubuisson J
    Hepatology; 2013 Jul; 58(1):86-97. PubMed ID: 23348596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.
    Castet V; Fournier C; Soulier A; Brillet R; Coste J; Larrey D; Dhumeaux D; Maurel P; Pawlotsky JM
    J Virol; 2002 Aug; 76(16):8189-99. PubMed ID: 12134024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
    Xu J; Liu S; Xu Y; Tien P; Gao G
    Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
    Haddad JG; Rouillé Y; Hanoulle X; Descamps V; Hamze M; Dabboussi F; Baumert TF; Duverlie G; Lavie M; Dubuisson J
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.
    Coburn GA; Fisch DN; Moorji SM; de Muys JM; Murga JD; Paul D; Provoncha KP; Rotshteyn Y; Han AQ; Qian D; Maddon PJ; Olson WC
    PLoS One; 2012; 7(4):e35351. PubMed ID: 22545104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.
    Scheel TK; Gottwein JM; Jensen TB; Prentoe JC; Hoegh AM; Alter HJ; Eugen-Olsen J; Bukh J
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):997-1002. PubMed ID: 18195353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
    Pawlotsky JM; Germanidis G; Frainais PO; Bouvier M; Soulier A; Pellerin M; Dhumeaux D
    J Virol; 1999 Aug; 73(8):6490-9. PubMed ID: 10400744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance.
    Zhu H; Nelson DR; Crawford JM; Liu C
    J Interferon Cytokine Res; 2005 Sep; 25(9):528-39. PubMed ID: 16181053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.